TY - JOUR
T1 - Antiviral drug discovery
T2 - preparing for the next pandemic
AU - Adamson, Catherine S
AU - Chibale, Kelly
AU - Goss, Rebecca J M
AU - Jaspars, Marcel
AU - Newman, David J
AU - Dorrington, Rosemary A
N1 - Acknowledgements
The authors also gratefully acknowledge financial support from the South African Medical Research Council (MRC) with funds received from the South African National Department of Health and the UK Government's Newton Fund (R. A. D., RL. M. G., K. C.), the UK Engineering and Physical Sciences Research Council EQATA (R. J. M. G.), the UK Global Challenge Research Fund (R. J. M. G., R. A. D.), the University of Cape Town (K. C.) and the South African Research Chairs Initiative of the Department of Science and Innovation, administered through the South African National Research Foundation (NRF) to K. C. (UID: 64767) and R. A. D. (UID: 87583). C. S. A. acknowledges financial support for SARS-CoV-2/Covid-19 research from UKMRC (CVG-1725-2020) and UKRI-DHSC (MR/Vo28464/1). The authors acknowledge Bronwyn Tweedie of the Rhodes University Print Services Unit who provided the graphics for Fig. 1 and thank Gordon Cragg for his insightful comments and encouragement during the preparation of this manuscript.
PY - 2021/3/21
Y1 - 2021/3/21
N2 - Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts.
AB - Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts.
KW - Antiviral Agents/chemistry
KW - Biological Products/chemistry
KW - COVID-19/drug therapy
KW - Coronavirus Protease Inhibitors/chemistry
KW - Drug Discovery/methods
KW - Humans
KW - Molecular Docking Simulation
KW - Molecular Targeted Therapy/methods
KW - Nucleic Acid Synthesis Inhibitors/chemistry
KW - Pandemics/prevention & control
KW - RNA, Viral/antagonists & inhibitors
KW - SARS-CoV-2/chemistry
KW - Small Molecule Libraries/chemistry
UR - http://www.scopus.com/inward/record.url?scp=85102078050&partnerID=8YFLogxK
U2 - 10.1039/d0cs01118e
DO - 10.1039/d0cs01118e
M3 - Article
C2 - 33524090
VL - 50
SP - 3647
EP - 3655
JO - Chemical Society Reviews
JF - Chemical Society Reviews
SN - 0306-0012
IS - 6
ER -
